Study on 72 Gy Radiation Therapy for Anaplastic Astrocytomas
Author Information
Author(s): Nomiya Takuma, Nemoto Kenji, Kumabe Toshihiro, Takai Yoshihiro, Yamada Shogo
Primary Institution: Tohoku University School of Medicine
Hypothesis
The study aims to verify the efficacy of 72 Gy hyperfractionated radiation therapy combined with chemotherapy for patients with anaplastic astrocytomas.
Conclusion
The study suggests that 72 Gy hyperfractionated radiation therapy shows a favorable outcome for patients with anaplastic astrocytoma with tolerable toxicity.
Supporting Evidence
- Three-year overall survival rate was 64.8%.
- Three-year progression-free survival rate was 64.4%.
- Three-year local control rate was 81.6%.
- The number of failures at 5 years was 14 (32%).
- One patient (2%) developed brain necrosis due to radiation therapy.
Takeaway
Doctors tested a special type of radiation treatment on patients with a brain tumor called anaplastic astrocytoma, and it helped many of them feel better without causing too much harm.
Methodology
Patients received 72 Gy of hyperfractionated radiation therapy in 60 fractions along with concurrent chemotherapy.
Potential Biases
Potential selection bias due to the single-arm design and exclusion of certain patients.
Limitations
The study had a limited sample size and was conducted at a single institution.
Participant Demographics
{"age_mean":39.8,"gender_distribution":{"male":30,"female":14},"karnofsky_score":{"80-100":27,"60-70":15,"40-50":2,"0-30":0},"site_of_lesion":{"frontal_lobe":23,"temporal_lobe":9,"parietal_lobe":3,"others":9},"tumor_size_median":5}
Statistical Information
Confidence Interval
{"overall_survival":"95% CI: 48.4–81.3%","progression_free_survival":"95% CI: 48.4–80.3%","local_control_rate":"95% CI: 69.2–94.8%"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website